<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26315613</article-id><article-id pub-id-type="pmc">4551529</article-id><article-id pub-id-type="publisher-id">141</article-id><article-id pub-id-type="doi">10.1186/s13195-015-0141-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hunter</surname><given-names>Sally</given-names></name><address><email>seh66@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Minett</surname><given-names>Thais</given-names></name><address><email>tsm34@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Polvikoski</surname><given-names>Tuomo</given-names></name><address><email>tuomo.polvikoski@newcastle.ac.uk</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Mukaetova-Ladinska</surname><given-names>Elizabeta</given-names></name><address><email>elizabeta.mukaetova-ladinska@newcastle.ac.uk</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Brayne</surname><given-names>Carol</given-names></name><address><email>cb105@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><collab>the Cambridge City over-75s Cohort Collaboration</collab></contrib><aff id="Aff1"><label/>Department of Public Health and Primary Care, Institute of Public Health, Forvie Site, University of Cambridge School of Clinical Medicine, Box 113 Cambridge Biomedical Campus, Cambridge, CB2 0SP UK </aff><aff id="Aff2"><label/>Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Cambridge Biomedical Campus, Cambridge, CB2 0QQ UK </aff><aff id="Aff3"><label/>Institute of Neuroscience, Henry Wellcome Building for Neuroecology, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>57</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Hunter et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is associated with neurofibrillary pathology, including neurofibrillary tangles (NFT), neuritic plaques (NP) and neuropil threads containing aggregated microtubule associated protein tau. Aggregated tau is also associated with granulovacuolar degeneration (GVD). The relationships between tau, GVD, NFT and dementia are unclear.</p></sec><sec><title>Methods</title><p>We assessed hippocampal (CA1) tau-immunoreactive GVD and NFT pathology in brain donations from the population-representative Cambridge City over 75s Cohort (CC75C) using the CERAD protocol and a modified protocol that included a morphological characterisation of tau-immunoreactive deposits within neurons as NFTs or as GVD. Associations between GVD, NFT and dementia were investigated.</p></sec><sec><title>Results</title><p>Hippocampal pyramidal neurons affected with either NFT or GVD are common in the older population. Some tau-immunoreactive deposits resemble ghost GVD neurons. Tau immunoreactivity identified GVD in 95&#x000a0;% cases rated as none with haematoxylin and eosin staining. Both severe NFT (odds ratio (OR) 7.33, 95&#x000a0;% confidence interval (CI) 2.01; 26.80, <italic>p</italic>&#x02009;=&#x02009;0.003) and severe GVD (OR 7.48, 95&#x000a0;%(CI) 1.54; 36.24, <italic>p</italic>&#x02009;=&#x02009;0.012) were associated with dementia status. Increasing NFT (OR 2.47 95&#x000a0;%(CI) 1.45; 4.22, <italic>p</italic>&#x02009;=&#x02009;0.001) and GVD (OR 2.12 95&#x000a0;%(CI) 1.23; 3.64, <italic>p</italic>&#x02009;=&#x02009;0.007) severities are associated with increasing dementia severity. However, when the analyses were controlled for other neuropathologies (NFT, NP, Tar-DNA binding Protein-43 and amyloid deposits), the associations between GVD and dementia lost significance.</p></sec><sec><title>Conclusions</title><p>Current neuropathological assessments do not adequately evaluate the presence and severity of the GVD pathology and its contribution to dementia remains unclear. We recommend that protocols to assess GVD should be developed for routine use and that tau, in a non-PHF associated conformation, is reliably associated with GVD.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13195-015-0141-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is characterised clinically by memory loss, cognitive impairment and behavioural problems [<xref ref-type="bibr" rid="CR1">1</xref>], and neuropathologically by neuronal and synaptic loss and by various deposits containing the amyloid-beta protein (A&#x003b2;) and aggregated microtubule-associated protein tau in the form of neurofibrillary pathologies including neurofibrillary tangles (NFT), dystrophic neurites in neuritic plaques (NP) and neuropil threads (NT) [<xref ref-type="bibr" rid="CR2">2</xref>]. Assessments of these lesions form the basis for the neuropathological confirmation of a clinical diagnosis of probable AD according to the Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD) protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and the assessment of tau-immunoreactive (IR) changes according to Braak stage [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The assessments for neuropathologically diagnosing AD have been updated recently to include assessments of A&#x003b2; deposits [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>The tau-associated pathologies, visualised by various methods and assessed using both the CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and Braak staging [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], include NFT, NP and NT. NFT are intracellular fibrous inclusions composed of paired helical filaments (PHFs) of aggregated and often hyperphosphorylated tau [<xref ref-type="bibr" rid="CR9">9</xref>]. The CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] counts only those neurons with mature, robustly staining NFT; those neurons with diffuse or granular staining are classified as pre-tangles and are not counted. The morphology of tau-IR cytoplasmic inclusions is not considered. The presence of extracellular ghost NFT, the remains of NFT after the neuron has died, are noted in both CERAD and Braak staging. These are assessed on haematoxylin and eosin (H &#x00026; E) or silver stained slides because many tau-IR epitopes associated with NFT are lost [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>In addition to the well-recognised AD-associated pathologies and argyrophilic grains in argyrophilic grain disease (AGD) [<xref ref-type="bibr" rid="CR11">11</xref>], various studies have demonstrated that the dense granules of granulovacuolar degeneration (GVD) also react with tau antibodies directed against various epitopes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>] but not those directed against some conformational epitopes specific for PHFs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The possibility of potential confusion relating to the interpretation of tau-IR pathology has been noted previously [<xref ref-type="bibr" rid="CR15">15</xref>]. GVD, first described by Teofil Simchowicz [<xref ref-type="bibr" rid="CR18">18</xref>], is characterised by neurons with two or more double membrane-bound cytoplasmic vacuoles containing an electron-dense granule [<xref ref-type="bibr" rid="CR19">19</xref>] and are usually assessed on H &#x00026; E slides. GVD is noted in the CERAD protocol as present or absent in the hippocampus [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. GVD is distinct from other tau-IR granules described previously that lack membrane enclosed vacuoles and have been interpreted as PHF core bodies [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>GVD within hippocampal pyramidal cells has previously been associated with increasing age and AD [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>] and is associated with intraneuronal accumulation of tau protein [<xref ref-type="bibr" rid="CR21">21</xref>]. GVD is also found in other neurodegenerative disorders, including Pick&#x02019;s disease, multiple system atrophy with Parkinsonism, amyotrophic lateral sclerosis with dementia, Down syndrome and progressive supranuclear palsy [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Previous work has suggested a possible progression of development for GVD [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], ranging from a few cytoplasmic granulovacuolar inclusions to neurons completely filled with granulovacuolar inclusions, which may follow topographical stages [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. While the association of GVD with AD has long been noted [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], a recent study estimating the contributions of rare or disregarded pathologies [<xref ref-type="bibr" rid="CR28">28</xref>] found no significant association between GVD and dementia when plaques and tangles were controlled for&#x02014;raising questions relating to the significance of GVD to dementia.</p><p>The literature reviewed suggests that the relationship between GVD and dementia is unclear and that there is potential for confusion in interpretations of tau-IR pathologies. We examined the pathology of tau-IR GVD and NFT in detail in the cornus ammonis (CA) fields of the hippocampus in the population-based Cambridge City over-75s Cohort (CC75C) with an antibody against the C-terminal portion of tau that is not dependent on phosphorylation or PHF-specific epitopes. We categorised neuronal tau pathology as NFT, GVD or mixed (NFT+GVD), and investigated how this detailed morphology relates to current assessments of GVD and tau pathology according to well-accepted protocols and relates to the associations between NFT, GVD and dementia.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>The study sample</title><p>CC75C is a population-based, longitudinal study of aging and dementia with a brain donation programme [<xref ref-type="bibr" rid="CR29">29</xref>]. Each study participant gave consent to participate and for brain donation. Consent for brain donation was also given by next of kin. Each phase of the CC75C study has been approved by the Cambridge Research Ethics Committee.</p><p>At the time of this study a total of 237 brain donations had CERAD measures, of which 211 cases were included for all analyses. Twenty five slides were not available or the area of interest was not present on the slide to score tau-IR GVD, NFT and GVD+NFT. For one slide, CA1 was not evaluable owing to complete neuronal loss.</p><p>A consensus diagnosis for dementia status at death consistent with <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> 4th edition (DSM-IV) criteria [<xref ref-type="bibr" rid="CR30">30</xref>] was agreed by clinicians, blinded to neuropathology reports, using post-mortem review of all clinical information including proxy informant data, death certificates and retrospective informant data after death. Dementia severity was rated as none, minimal, mild, moderate and severe [<xref ref-type="bibr" rid="CR31">31</xref>]. Where dementia severity could not be rated it was scored as unknown.</p></sec><sec id="Sec4"><title>Neuropathological protocols</title><p>Brain collection for this study occurred between 1989 and 2009. After death, the brains were removed as soon as possible in the local mortuary. The brains were bisected in the sagittal plane. One cerebral hemisphere was dissected coronally into approximately 1&#x000a0;cm slices, macroscopically examined and then snap-frozen to &#x02013;80&#x000a0;&#x000b0;C. The other half of the brain was fixed in formalin for at least 6&#x000a0;weeks and dissected coronally into approximately 1&#x000a0;cm slices. For diagnostic purposes, tissue blocks for paraffin embedding were taken from the hippocampus (at the level of the lateral geniculate body), entorhinal cortex (at the level of the mammillary body), frontal, temporal, parietal and occipital lobes, basal ganglia, thalamus, pons, medulla, cerebellum and two levels of the midbrain. Serial sections from the paraffin-embedded brain tissue samples were assessed for neuropathology blind to clinical status according to the CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and Braak stage [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. All slides were produced by the Cambridge Brain Bank, Cambridge, UK and assessments were performed blind to clinical status by neuropathologists at Addenbrooke&#x02019;s Hospital, Cambridge, UK. All immunostained sections for diagnosis were counterstained with Ehrlich&#x02019;s haematoxylin with diaminobenzidine as the chromagen.</p><p>Lewy bodies were assessed as present or absent using 10 &#x003bc;m sections stained with H &#x00026; E in combination with slides stained with anti-ubiquitin antibody (pAb BR 251, Z0458; DAKO, Glostrup, Denmark) (first 174 donations) or with anti-&#x003b1;-synuclein (SA3400; Biomol International, Enzo Life Sciences, Farmingdale, New York, USA) (last 63 cases). A&#x003b2; deposits as senile plaques and cerebral amyloid angiopathy (CAA) were visualised with Congo red and/or anti-A&#x003b2; antibody (M872, Clone 6&#x000a0;F/3D; DAKO) on 10&#x000a0;&#x003bc;m sections and assessed as none, mild, moderate or severe according to the CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Inclusions reactive with tar-DNA binding protein 43 (TDP-43) were assessed using 9&#x000a0;&#x003bc;m sections from the hippocampus and entorhinal cortex stained with anti-TDP-43 antibody (pS409/410-2; Cosmo Bio Co. Ltd, Tokyo, Japan). Slides were counterstained with Harris&#x02019; haematoxylin with diaminobenzidine as the chromagen. Solid neuronal inclusions were assessed, based on the protocol in Neumann et al. [<xref ref-type="bibr" rid="CR32">32</xref>], as none (no inclusions), minimal (one inclusion per slide), mild (one or more inclusions in up to half the fields of view per slide), moderate (a few inclusions in over half the fields of view per slide) or severe (a few inclusions in most fields of view per slide).</p><p>Sections 10&#x000a0;&#x003bc;m thick from the hippocampus and entorhinal cortex were immunostained with anti-tau monoclonal antibody (mAb) 11.57 (supplied by The Cambridge Brain Bank, dilution 1:5; gift donated by Professor Claude Wischik, University of Aberdeen, UK) to visualise NFT, NP and dystrophic neurites. mAb 11.57 was raised against a pronase-treated PHF core sub-fraction and recognises a phosphorylation and conformation-independent epitope in the C-terminal region of tau [<xref ref-type="bibr" rid="CR12">12</xref>]. mAb 11.57 recognises NFT, NP, NT and GVD bodies and the grains of AGD but not ghost NFT [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. During the diagnostic process, an experienced neuropathologist scored the severity of NFT according to the CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] as either none, mild, moderate or severe. GVD, defined as neurons with two or more membrane-bound cytoplasmic vacuoles containing a basophilic granule, was rated according to the CERAD protocol [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] as present or absent on hippocampal sections 10&#x000a0;&#x003bc;m thick stained with H &#x00026; E.</p><p>A second protocol was designed to assess the separate tau-IR pathologies based on morphology. Tau-IR NFT (defined as neurons with fibrous deposits of tau and no vacuoles containing an electron dense granule), tau-IR GVD (defined as neurons with two or more membrane-bound cytoplasmic vacuoles containing a tau-IR dense granule and no fibres) and neurons containing mixed pathology with both fibrous and granulovacuolar pathology (NFT+GVD) were scored at 100&#x000d7; magnification as none, an isolated example per area, and as mild, moderate or severe by comparison with the references images for NFT from the CERAD protocol [<xref ref-type="bibr" rid="CR3">3</xref>]. The same slides were assessed with both protocols. Higher magnifications (200&#x000d7; and 400&#x000d7;) were used to assess the detailed morphology of any tau-IR structures that could not be classified at lower magnification (100&#x000d7;). Separate scores for the hippocampal regions CA1 and CA2&#x02013;3, the regions most associated with tau immunoreactivity, were generated by SH and inter-rated by TP. Regions CA2 and CA3 were combined for scoring owing to difficulties in reliably defining the CA2&#x02013;CA3 boundary. Photomicrographs were taken with a Leica DM LB microscope with a DC500 digital camera Wetzlar, Germany.</p></sec><sec id="Sec5"><title>Inter-rater analysis</title><p>The extent of agreement between two raters (SH and TP) in relation to severity of NFT, GVD and NFT+GVD in CA1 and CA2&#x02013;3 was assessed by calculating Gwet&#x02019;s AC2 coefficients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). This is a paradox-resistant alternative to Kappa&#x02019;s coefficient when the overall percentage agreement is high [<xref ref-type="bibr" rid="CR34">34</xref>]. The coefficient calculations were performed using Agreestat 2011.2 (Advanced Analytics, Gaithersburg, MD, USA). The extent of agreement was assessed using the benchmark proposed by Landis and Koch [<xref ref-type="bibr" rid="CR35">35</xref>]; a coefficient &#x0003e;0.6 indicates substantial agreement and a value &#x0003e;0.8 near-perfect agreement. In general, NFT and GVD were seen to have AC2 coefficients &#x0003e;0.6, implying substantial agreement, which was more marked in CA1 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The only exception was for NFT+GVD in CA2&#x02013;3 (AC2&#x02009;=&#x02009;0.13), where agreement was poor. This was most probably due to a combination of differences in assigning the CA1/CA2 boundary and the rarity of neurons with both tau-IR NFT and GVD pathologies. Data for NFT+GVD were not included in further analyses.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inter-rater reliability on tau-IR GVD, NFT and GVD+NFT by hippocampal area</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>AC2</th><th>SE</th><th>95&#x000a0;% CI (AC2)</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="5">CA2&#x02013;3</td></tr><tr><td>&#x02003;NFT</td><td>0.73</td><td>0.11</td><td>0.51&#x02013;0.95</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;NFT+GVD</td><td>0.13</td><td>0.22</td><td>&#x02212;0.33 to 0.58</td><td>0.568</td></tr><tr><td>&#x02003;GVD</td><td>0.67</td><td>0.09</td><td>0.49&#x02013;0.85</td><td>&#x0003c;0.001</td></tr><tr><td colspan="5">CA1</td></tr><tr><td>&#x02003;NFT</td><td>0.89</td><td>0.06</td><td>0.77&#x02013;1.00</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;NFT+GVD</td><td>0.76</td><td>0.09</td><td>0.57&#x02013;0.96</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;GVD</td><td>0.76</td><td>0.08</td><td>0.60&#x02013;0.92</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>
<italic>AC2</italic> Gwet&#x02019;s coefficient, <italic>CA</italic> cornus ammonis, <italic>CI</italic> confidence interval, <italic>GVD</italic> granulovacuolar degeneration, <italic>NFT</italic> neurofibrillary tangles, <italic>SE</italic> standard error</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Inter-rater reliability was not substantial for NFT+GVD in CA2&#x02013;3, so further analyses were restricted to NFT and GVD in the CA1 area only. The mean (standard deviation) is presented when applicable.</p><p>The relationships between tau-IR GVD and NFT with dementia status were verified using logistic regression. Dementia status was defined as the dependent variable and tau-IR scores in CA1 as independent variables. Three hierarchical models were created: model 1 controlled for sex and age at death; model 2 was additionally controlled for NFT and NP; and model 3 additionally controlled for TDP-43 and amyloid deposits. The same approach was used to verify the relationships between tau-IR GVD and NFT with dementia severity, using ordinal logistic regression.</p><p>The Spearman coefficient (<italic>r</italic>) was calculated to verify the relationships between different pathologies and different protocols. All tests were two-tailed. Statistical analyses were performed using statistical package STATA, version 12 College Station, Texas, USA.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>In total, 211 brains were included in the sample. Among them, 147 (70&#x000a0;%) were women. Mean age of death was 90.97 (4.51) years. Dementia status at death could not be determined in eight (4&#x000a0;%) participants, 71 (34&#x000a0;%) did not have dementia and 132 (63&#x000a0;%) had dementia at death.</p><p>Both NFT and GVD were common; using the new protocol, 91&#x000a0;% of the cases surveyed showed both GVD and NFT in the hippocampal CA1 fields, 1&#x000a0;% had NFT with no GVD, 4&#x000a0;% had GVD with no NFT and 4&#x000a0;% had neither NFT nor GVD pathology.</p><sec id="Sec8"><title>Relationship between CERAD assessments and the new protocol</title><p>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> presents a comparison between CERAD protocol GVD scores (columns) and the morphologically separated tau-IR GVD scores from the modified protocol (rows). Assessments using H &#x00026; E slides underestimated GVD pathology: 95&#x000a0;% (54/57) of cases scored as having no GVD according to the CERAD protocol were scored as having at least mild GVD in CA1 according to the tau-IR stain.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of GVD scores from the two protocols</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">CERAD protocol GVD score</th></tr><tr><th>Tau-IR GVD score<sup>a</sup>
</th><th>No</th><th>Yes</th></tr></thead><tbody><tr><td>No</td><td>3 (5)</td><td>1 (1)</td></tr><tr><td>Mild</td><td>21 (37)</td><td>18 (26)</td></tr><tr><td>Moderate</td><td>21 (37)</td><td>31 (45)</td></tr><tr><td>Severe</td><td>12 (21)</td><td>19 (28)</td></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%). Some GVD scores were marked as missing from the CERAD assessment, and therefore data are for cases which did have CERAD GVD scores (<italic>n</italic>&#x02009;=&#x02009;126)</p><p>
<sup>a</sup>From the modified protocol</p><p>
<italic>CERAD</italic> Consortium to Establish a Registry for Alzheimer disease, <italic>GVD</italic> granulovacuolar degeneration, <italic>IR</italic> immunoreactive</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> compares CERAD scores for NFT with those from the new protocol. Even though both the CERAD protocol and our modified tau-IR protocol scores represent the CA1 area, the correlation between those NFT scores was moderate (<italic>n</italic>&#x02009;=&#x02009;126, <italic>r</italic>&#x02009;=&#x02009;0.67, <italic>p</italic> &#x0003c;0.001).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of NFT scores from the two protocols</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">CERAD protocol NFT score</th></tr><tr><th>Tau-IR NFT score<sup>a</sup>
</th><th>No</th><th>Mild</th><th>Moderate</th><th>Severe</th></tr></thead><tbody><tr><td>No</td><td>2 (67)</td><td>8 (17)</td><td>4 (5)</td><td>2 (3)</td></tr><tr><td>Mild</td><td>1 (33)</td><td>31 (67)</td><td>26 (32)</td><td>3 (4)</td></tr><tr><td>Moderate</td><td>0 (0)</td><td>7 (15)</td><td>40 (49)</td><td>27 (34)</td></tr><tr><td>Severe</td><td>0 (0)</td><td>0 (0)</td><td>11 (14)</td><td>48 (60)</td></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%). One score for NFT was marked as missing, and therefore data are for cases which did have CERAD NFT scores (<italic>n</italic>&#x02009;=&#x02009;210)</p><p>
<sup>a</sup>From the modified protocol</p><p>
<italic>CERAD</italic> Consortium to Establish a Registry for Alzheimer disease, <italic>IR</italic> immunoreactive, <italic>NFT</italic> neurofibrillary tangles</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Relationship between NFT and GVD</title><p>Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> compares the scores for NFT and GVD according to the CERAD protocol assessments.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Relationship between CERAD scores for NFT and GVD</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">CERAD protocol NFT score</th></tr><tr><th>CERAD protocol GVD score</th><th>No</th><th>Mild</th><th>Moderate</th><th>Severe</th></tr></thead><tbody><tr><td>No</td><td>1 (100)</td><td>15 (43)</td><td>18 (43)</td><td>23 (48)</td></tr><tr><td>Yes</td><td>0 (0)</td><td>20 (57)</td><td>24 (57)</td><td>25 (52)</td></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%)</p><p>
<italic>CERAD</italic> Consortium to Establish a Registry for Alzheimer disease, <italic>GVD</italic> granulovacuolar degeneration, <italic>NFT</italic> neurofibrillary tangles</p></table-wrap-foot></table-wrap></p><p>There was no significant correlation between NFT and GVD assessed with the CERAD protocol (<italic>n</italic>&#x02009;=&#x02009;126, <italic>r</italic>&#x02009;=&#x02009;&#x02212;0.03, <italic>p</italic>&#x02009;=&#x02009;0.760).</p><p>Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> compares the scores for NFT and GVD according to the new tau-IR protocol.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Relationship between new protocol scores for NFT and GVD</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">NFT score from tau-IR protocol</th></tr><tr><th>GVD score from tau-IR protocol</th><th>No</th><th>Mild</th><th>Moderate</th><th>Severe</th></tr></thead><tbody><tr><td>No</td><td>8 (50)</td><td>1 (2)</td><td>0 (0)</td><td>2 (3)</td></tr><tr><td>Mild</td><td>7 (44)</td><td>38 (62)</td><td>9 (12)</td><td>3 (5)</td></tr><tr><td>Moderate</td><td>1 (6)</td><td>22 (36)</td><td>45 (60)</td><td>21 (36)</td></tr><tr><td>Severe</td><td>0 (0)</td><td>0 (0)</td><td>21 (28)</td><td>33 (56)</td></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%)</p><p>
<italic>GVD</italic> granulovacuolar degeneration, <italic>IR</italic> immunoreactive, <italic>NFT</italic> neurofibrillary tangles</p></table-wrap-foot></table-wrap></p><p>There was moderate correlation between NFT and GVD using the new tau-IR protocol (<italic>n</italic>&#x02009;=&#x02009;211, <italic>r</italic>&#x02009;=&#x02009;0.65, <italic>p</italic> &#x0003c;0.001).</p></sec><sec id="Sec10"><title>Relationships between dementia and tau-IR pathologies</title><p>Analyses for tau-IR were conducted on 211 brain donations. Only two cases with hippocampal Lewy body pathology and only a few cases with moderate/severe CAA were identified; these neuropathologies were therefore not included in further analyses. The distributions between dementia severity and various hippocampal neuropathologies are shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p><p>The relationship between dementia and tau-IR GVD was verified by logistic regression with dementia status as the dependent variable and tau-IR GVD in CA1 status as the independent variable. The analysis was controlled by sex and age at death in model 1 (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>). Severe tau-IR GVD was significantly related to dementia regardless of sex and age of death; however, when the analyses were also controlled by NFT and NP (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>, model 2), the relationship between dementia and severe tau-IR GVD lost significance. The loss of significance remained when hippocampal TDP-43 and amyloid deposits (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>) were controlled for (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>, model 3).<table-wrap id="Tab6"><label>Table 6</label><caption><p>Logistic regression models showing the relationships between hippocampal pathologies and presence of clinical dementia</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Model 1</th><th colspan="3">Model 2</th><th colspan="3">Model 3</th></tr><tr><th/><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="10">GVD-IR</td></tr><tr><td>&#x02003;Mild</td><td>1.04</td><td>(0.25&#x02013;4.38)</td><td>0.956</td><td>1.00</td><td>(0.23&#x02013;4.35)</td><td>1.000</td><td>1.00</td><td>(0.22&#x02013;4.52)</td><td>0.998</td></tr><tr><td>&#x02003;Moderate</td><td>1.55</td><td>(0.38&#x02013;6.31)</td><td>0.542</td><td>1.07</td><td>(0.24&#x02013;4.76)</td><td>0.931</td><td>1.03</td><td>(0.22&#x02013;4.80)</td><td>0.972</td></tr><tr><td>&#x02003;Severe</td><td>7.48</td><td>(1.54&#x02013;36.24)</td><td>0.012</td><td>3.90</td><td>(0.71&#x02013;21.45)</td><td>0.118</td><td>3.81</td><td>(0.65&#x02013;22.41)</td><td>0.139</td></tr><tr><td colspan="10">NFT-IR</td></tr><tr><td>&#x02003;Mild</td><td>1.21</td><td>(0.37&#x02013;3.93)</td><td>0.753</td><td>1.26</td><td>(0.38&#x02013;4.25)</td><td>0.705</td><td>1.39</td><td>(0.36&#x02013;5.45)</td><td>0.635</td></tr><tr><td>&#x02003;Moderate</td><td>2.27</td><td>(0.70&#x02013;7.31)</td><td>0.170</td><td>1.66</td><td>(0.46&#x02013;5.98)</td><td>0.435</td><td>2.61</td><td>(0.61&#x02013;11.19)</td><td>0.198</td></tr><tr><td>&#x02003;Severe</td><td>7.33</td><td>(2.01&#x02013;26.80)</td><td>0.003</td><td>4.86</td><td>(1.17&#x02013;20.28)</td><td>0.030</td><td>9.99</td><td>(1.97&#x02013;50.54)</td><td>0.005</td></tr></tbody></table><table-wrap-foot><p>Model 1 controlling for age and sex; model 2 additionally controlling for NFT and NP; model 3 additionally controlling for TDP-43 and amyloid deposits</p><p>
<italic>CI</italic> confidence interval, <italic>GVD</italic> granulovacuolar degeneration, <italic>IR</italic> immunoreactive, <italic>NFT</italic> neurofibrillary tangles, <italic>NP</italic> neuritic plaques, <italic>OR</italic> odds ratio, <italic>TDP-43</italic> Tar-DNA binding protein 43</p></table-wrap-foot></table-wrap></p><p>The relationships between dementia severity and severity of tau-IR GVD and NFT were tested using ordinal logistic regressions controlling for sex and age at death in model 1 (Table&#x000a0;<xref rid="Tab7" ref-type="table">7</xref>). For these analyses, tau-IR scores were dichotomised into none/isolated/mild vs. moderate/severe. Increasing tau-IR GVD and tau-IR NFT severities were significantly associated with increasing dementia severity (Table&#x000a0;<xref rid="Tab7" ref-type="table">7</xref>, model 1). However, when the analysis was also controlled by NFT and NP (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>), the relationship between dementia severity and tau-IR GVD was weaker and lost significance (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>, model 2). The loss of significance remained when hippocampal TDP-43 and amyloid deposits (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>) were controlled for (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>, model 3).<table-wrap id="Tab7"><label>Table 7</label><caption><p>Ordinal logistic regression models showing the relationships between hippocampal pathologies and severity of clinical dementia</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Model 1</th><th colspan="3">Model 2</th><th colspan="3">Model 3</th></tr><tr><th/><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th><th>OR</th><th>CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>GVD-IR</td><td>2.12</td><td>(1.23&#x02013;3.64)</td><td>0.007</td><td>1.30</td><td>(0.69&#x02013;2.44)</td><td>0.422</td><td>1.31</td><td>(0.68&#x02013;2.54)</td><td>0.417</td></tr><tr><td>NFT-IR</td><td>2.47</td><td>(1.45&#x02013;4.22)</td><td>0.001</td><td>1.61</td><td>(0.84&#x02013;3.10)</td><td>0.152</td><td>3.16</td><td>(1.48&#x02013;6.71)</td><td>0.003</td></tr></tbody></table><table-wrap-foot><p>Model 1 controlling for age and sex; model 2 additionally controlling for NFT and NP; model 3 additionally controlling for TDP-43 and amyloid deposits</p><p>
<italic>CI</italic> confidence interval, <italic>GVD</italic> granulovacuolar degeneration, <italic>IR</italic> immunoreactive, <italic>NFT</italic> neurofibrillary tangles, <italic>NP</italic> neuritic plaques, <italic>OR</italic> odds ratio, <italic>TDP-43</italic> Tar-DNA binding protein 43</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Descriptions of tau-IR pathology</title><p>Hippocampal pyramidal neurons can develop NFT, GVD or, less commonly, co-existing GVD and NFT as illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>GVD and NFT at the CA2&#x02013;CA1 boundary. <bold>a</bold> CA2&#x02013;CA1 boundary at 159&#x000d7; magnification; scale bar&#x02009;=&#x02009;100&#x000a0;&#x003bc;m. <bold>b</bold> Marked area in A at 638&#x000d7; magnification; scale bar&#x02009;=&#x02009;20&#x000a0;&#x003bc;m: 1 NFT bearing neuron, 2, 3 neurons with both GVD granules and fibrils that under low power in A could be mistaken for &#x02018;pure&#x02019; NFT, 4 two neurons with diffuse tau staining lacking any clear morphology and showing a clear hard line around the nucleus, 5 a neuron with GVD also containing two larger discrete fibrous bundles, *examples of neurons with GVD. <bold>c</bold> The cell marked 3 at 1600&#x000d7; magnification showing GVD and fibrils; scale bar&#x02009;=&#x02009;20&#x000a0;&#x003bc;m. <italic>CA</italic> cornus ammonis, <italic>GVD</italic> granulovacuolar degeneration, <italic>NFT</italic> neurofibrillary tangles</p></caption><graphic xlink:href="13195_2015_141_Fig1_HTML" id="MO1"/></fig></p><p>In Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>, GVD granules in neurons can be seen to range from a few weakly staining, and very rarely, non-staining granules within a neuron to an increasing number of membrane-enclosed granules until the whole cell body is filled with intensely staining GVD. Distended neuronal bodies with large swollen GVD bodies can also be seen (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>, neuron 5). This can be compared with the well-accepted progression in NFT ranging from a few lightly stained cytoplasmic filaments (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b, c</xref>, neurons i) to robustly staining mature fibrous NFT (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b, c</xref>, neurons ii), with ghost NFT as an end stage (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>, area iii). There is a possibility that advanced stages of GVD could be mistaken for NFT, as seen in Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. The CA2 area at low power in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> appears to contain at least three neurons with robustly staining cytoplasmic inclusions, but at higher magnifications only one neuron from the marked area contains NFT, with others showing advanced GVD or a combination of GVD-like and fibrous inclusions.<fig id="Fig2"><label>Fig. 2</label><caption><p>GVD and NFT progression in the hippocampal CA1 field. <bold>a</bold> Neurons in CA1 at 638&#x000d7; magnification showing various stages of GVD pathology: 1 a few granules in the neuronal cytoplasm staining weakly and one granule not at all for tau, 2, 3 more cytoplasmic granules develop and tau staining increases in intensity, 4 the cell body is completely filled with strongly staining small GVD and could be mistaken for NFT, 5 the neuron appears distended and the cell body is filled with large GVD with distended vacuoles. <bold>b</bold>, <bold>c</bold>, <bold>d</bold> CA1 neurons showing NFT progression at 638&#x000d7; magnification: i neurons showing a possible early stage of NFT formation with lightly staining PHF fibres, ii neurons showing robust tau staining of fibrous PHFs, iii ghost tangle. Scale bar&#x02009;=&#x02009;20&#x000a0;&#x003bc;m. <italic>CA</italic> cornus ammonis, <italic>GVD</italic> granulovacuolar degeneration, <italic>NFT</italic> neurofibrillary tangles, <italic>PHF</italic> paired helical filament</p></caption><graphic xlink:href="13195_2015_141_Fig2_HTML" id="MO2"/></fig></p><p>Very rarely, neurons with GVD also contained one or more discrete fibrous bundles (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, neuron 5) that could not be classified as NFT or GVD/NFT mixed and so were not included in the assessments. Pyramidal neurons with diffuse cytoplasmic tau reactivity, often with a defined line around the nucleus (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, neurons 4) and previously described in association with AGD [<xref ref-type="bibr" rid="CR36">36</xref>], seen in the hippocampal areas CA1, CA2 and CA3 were also not included in assessments for this study.</p><p>In addition to the well-recognised ghost tangles associated with NFT, we also found what appeared to be extracellular ghost GVD, showing clear granulovacuolar inclusions but no evidence of a living neuron, examples of which are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. Unlike ghost NFT, these retained reactivity with mAb 11.57.<fig id="Fig3"><label>Fig. 3</label><caption><p>End stage &#x02018;ghost&#x02019; GVD. <bold>a</bold>&#x02013;<bold>f</bold> Examples of possible &#x02018;ghost&#x02019; GVD. All panels at 638&#x000d7; magnification; scale bar&#x02009;=&#x02009;20&#x000a0;&#x003bc;m. <italic>Arrows</italic>, deposits resembling neurons with GVD but with no discernible living cell body or nucleus. <italic>GVD</italic> granulovacuolar degeneration</p></caption><graphic xlink:href="13195_2015_141_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p>We found more GVD pathology using tau-IR than was detected by H &#x00026; E, suggesting that GVD is missed with current protocols. The associations between dementia and both hippocampal (CA1) NFT and GVD are significant. Additionally, the severity of both NFT and GVD were significantly associated with dementia severity. However, the association between GVD and dementia lost significance when NFT, NP and other pathologies were controlled for.</p><p>We find that there is a potential for misinterpretation of tau pathology. Since many anti-tau antibodies react with both NFT and GVD, there is potential for neurons with GVD to be mistaken for pre-tangles and neurons with severe GVD to be mistaken for NFT at low magnifications. We also found tau-IR deposits resembling ghost GVD neurons that appeared morphologically different from ghost NFT.</p><p>This study has limitations. The selection of anti-tau immunostained slides used in this study was from the historical diagnostic collection and assessments were semi-quantitative and not stereological [<xref ref-type="bibr" rid="CR37">37</xref>]; this may introduce bias because we assume a single slide will represent a specific case adequately. Since comparison of the scoring protocols required that we use the same diagnostic slides, missing slides&#x02014;perhaps due to breakage over the ~25&#x000a0;years of the study to date&#x02014;may introduce bias.</p><p>Our assessments of Lewy bodies are based on older protocols for 174/241 cases and therefore scores for Lewy bodies might be underestimates. Both hippocampal Lewy bodies and CAA were rare and not included in analyses.</p><p>In any study of this type, brains donated at death represent a cross-section of the cohort at a specific terminal point. While the presentation of GVD morphology in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> appears to represent a progression of increasing severity, this is not certain. Additionally, the morphological similarity of structures in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> to ghost GVD neurons is circumstantial. These interpretations would need to be confirmed by longitudinal studies.</p><p>Of the 211 cases included in our study, only 126 had measures for GVD from the CERAD protocol. It is possible that GVD was not seen on H &#x00026; E staining and therefore no measure was recorded. Alternatively, historically GVD has not been prioritised as a dementia-related pathology and therefore GVD assessments may have been neglected. We did not use a second marker for GVD; however, we were very careful to count only neurons containing two or more structures with a dense granule surrounded by the halo of a vacuole and it is unlikely that we have overestimated GVD. A marker for GVD has yet to be validated and, given our poor correlations between GVD and NFT as assessed using the CERAD protocol, a consensus regarding the reliability of GVD markers is required.</p><p>Tau-IR reliably marks nearly all dense granules associated with GVD and we identified more cases with tau-IR GVD than with the standard assessment protocol using H &#x00026; E staining. Similarly, a study using antibodies to tubulin found four times more GVD than H &#x00026; E alone [<xref ref-type="bibr" rid="CR38">38</xref>], and the phosphorylated ribosomal protein S6 (pS6) revealed more neurons containing both NFT and GVD than in our study [<xref ref-type="bibr" rid="CR39">39</xref>], suggesting that GVD can be missed in standard neuropathological protocols using H &#x00026; E. Thal et al. [<xref ref-type="bibr" rid="CR15">15</xref>] suggest that tau is not a good marker for GVD owing to its involvement with various pathologies, and another candidate marker for GVD (pS6) revealed more neurons containing both NFT and GVD than in our study [<xref ref-type="bibr" rid="CR39">39</xref>]; therefore it is possible that GVD-IR is masked by immunoreactivity for NFT and that our measures underestimate GVD when present in NFT.</p><p>Our more detailed assessment of tau-IR NFT correlated with that of the CERAD protocol moderately. The CERAD score represents the highest score measured over the entire hippocampal structure and our detailed score is for CA1 only. However, since CA1 is often the most severely affected hippocampal structure [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], we would expect good correlation. If the morphology of tau-IR is not considered, there is potential for occasional neurons severely affected by GVD and neurons with both GVD and NFT to be misclassified as pure NFT, as illustrated in Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. This may also contribute to the moderate correlation found.</p><p>We found a significant association between both NFT and GVD with dementia. However, when NFT and NP were controlled for, the association between GVD and dementia lost significance. This is in agreement with results from the study by Keage et al. [<xref ref-type="bibr" rid="CR28">28</xref>]. In agreement with Ball [<xref ref-type="bibr" rid="CR40">40</xref>], our results suggest that GVD severity increases as NFT severity increases. A loss of significance can mean that GVD is not an independent contributor to dementia and so is &#x02018;unimportant&#x02019; or that there is some mechanism involving GVD, NFT and plaques that undermines the assumption of independence for this statistical test. With increasing evidence that NFT and GVD share some features, including tau, and not others (e.g., TDP-43 [<xref ref-type="bibr" rid="CR41">41</xref>]), it is possible that loss of significance reflects some shared process(es) rather than GVD not being an important contributor to dementia. At a mechanistic level, various studies imply that GVD is a pre-tangle and/or contributes to early NFT formation [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. This conflicts with other studies [<xref ref-type="bibr" rid="CR12">12</xref>], including ours, which present evidence that GVD can be interpreted as a separate process.</p><p>Our estimates of the associations between both severities of GVD and NFT and dementia status may be unreliable because only CA1 scores were included. For a future detailed investigation of the relationships between NFT, GVD and dementia, neocortical and subcortical areas should be included [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>In agreement with Bondareff et al. [<xref ref-type="bibr" rid="CR12">12</xref>], in each available case from the CC75C cohort affected by both NFT and GVD we have observed neurons with classic fibrillar NFT only, classic GVD only and, more rarely, neurons with both NFT and GVD (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). While these pathologies can rarely occur together in the same neuron, we do not see neurons in which GVD-like deposits can be interpreted as developing into NFT following the generally accepted progression from pre-tangle to mature NFT to ghost tangle as the CERAD protocol and other studies imply [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Rather, NFT and GVD appear to have their own progression in severity (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) and their own ghost forms (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). Given the associations between GVD and NFT and dementia presented, our evidence supports previous suggestions that the formation of NFT and GVD are separate processes that can co-occur in any individual [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>In comparison, the accepted longitudinal progression for NFT from pre-tangles to mature tangles to extracellular ghosts is also based on similar cross-sectional studies. Our findings suggest that the widely accepted progression of NFT may not be adequate to explain the variations in tau-IR we present. We suggest that the pathways of both granulovacuolar and neurofibrillary tau-IR pathology require careful evaluation to separate and understand the relationships between these two processes and their involvement in dementia. Additional processes may relate to diffuse tau-IR seen in neurons marked in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and these may be associated with AGD [<xref ref-type="bibr" rid="CR36">36</xref>]. Definitions of what a pre-tangle is need clarification.</p><p>Most GVD granules are labelled strongly with tau, suggesting that tau is involved in the development of GVD at an early stage. GVD shows an amorphous structure on electron micrographs [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], shows no fluorescence with thioflavin S [<xref ref-type="bibr" rid="CR13">13</xref>] and is not marked by mAbs such as 7.51 [<xref ref-type="bibr" rid="CR12">12</xref>], Alz-50 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], Tau-1 [<xref ref-type="bibr" rid="CR17">17</xref>] and PHF-1 [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] recognising epitopes specific to PHFs. The above evidence suggests that PHFs, typical of NFT, are not contained in GVD. Tau aggregation in GVD has been interpreted as representing a second pathway of tau aggregation [<xref ref-type="bibr" rid="CR12">12</xref>]. Tau as a component of GVD will be missed when using PHF reactive antibodies. Why some neurons develop NFT, GVD or occasionally both is not known but could arise owing to different stress responses in different neuronal subtypes, different neurodegenerative processes or different stress responses within the neurons. Investigations into the initiation and development of GVD may offer alternative therapeutic targets.</p></sec><sec id="Sec13" sec-type="conclusion"><title>Conclusions</title><p>Tau in a non-PHF-associated conformation is reliably associated with GVD. Current neuropathological protocols do not adequately capture the extent of tau-IR pathology and require re-evaluation, in particular, to better assess the contribution of GVD to dementia and differentiate it from pathology of NFT. The relationships between NFT, GVD and pre-tangles are unclear, which has consequences for investigations into tau aggregation, especially at early stages of disease. We recommend that protocols to assess GVD should be developed for routine use.</p></sec></body><back><app-group><app id="App1"><sec id="Sec14"><title>Additional file</title><p><media position="anchor" xlink:href="13195_2015_141_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Presenting the severity of hippocampal pathologies with dementia severity. <italic>n</italic> (row%); NFT-IR data from the new protocol; NFT (CERAD) data from the CERAD protocol. (DOC 80&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>A&#x003b2;</term><def><p>Amyloid-beta protein</p></def></def-item><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>AGD</term><def><p>Argyrophilic grain disease</p></def></def-item><def-item><term>CA</term><def><p>Cornus ammonis</p></def></def-item><def-item><term>CAA</term><def><p>Cerebral amyloid angiopathy</p></def></def-item><def-item><term>CC75C</term><def><p>Cambridge City over 75s Cohort</p></def></def-item><def-item><term>CERAD</term><def><p>Consortium to Establish a Registry for Alzheimer&#x02019;s Disease</p></def></def-item><def-item><term>DSM-IV</term><def><p><italic>Diagnostic and Statistical Manual of Mental Disorders</italic> 4th edition</p></def></def-item><def-item><term>GVD</term><def><p>Granulovacuolar degeneration</p></def></def-item><def-item><term>H &#x00026; E</term><def><p>Haematoxylin and eosin</p></def></def-item><def-item><term>IR</term><def><p>Immunoreactive</p></def></def-item><def-item><term>mAb</term><def><p>Monoclonal antibody</p></def></def-item><def-item><term>NFT</term><def><p>Neurofibrillary tangles</p></def></def-item><def-item><term>NP</term><def><p>Neuritic plaques</p></def></def-item><def-item><term>NT</term><def><p>Neuropil threads</p></def></def-item><def-item><term>PHF</term><def><p>Paired helical filament</p></def></def-item><def-item><term>pS6</term><def><p>Phosphorylated ribosomal protein S6</p></def></def-item><def-item><term>TDP-43</term><def><p>Tar-DNA binding protein 43</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>SH designed the study, conducted the morphologically based, tau-IR neuropathological surveys and drafted and revised the manuscript. TM designed and conducted all analyses and drafted and revised the manuscript. TP performed the inter-rater survey and drafted and revised the manuscripts. EM-L drafted and revised the manuscript. CB drafted and revised the manuscript. The CC75C collaboration designed the study, generated various clinical and neuropathological (CERAD) data and revised the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank all of the participants, families and carers in the CC75C study. CC75C is a member study of the Cambridgeshire and Peterborough Collaboration for Leadership in Applied Health Research and Care (CLAHRC). The Cambridge Brain Bank Laboratory (which processed all CC75C cases) is supported by the National Institute for Health Research, Cambridge BioMedical Research Centre. EM-L is supported by the Alzheimer&#x02019;s Society (London, UK).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>Mohs</surname><given-names>RC</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Fillenbaum</surname><given-names>G</given-names></name><etal/></person-group><article-title>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease</article-title><source>Neurology</source><year>1989</year><volume>39</volume><fpage>1159</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1212/WNL.39.9.1159</pub-id><pub-id pub-id-type="pmid">2771064</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>McKeel</surname><given-names>D</given-names></name><name><surname>Sumi</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Brownlee</surname><given-names>LM</given-names></name><etal/></person-group><article-title>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>479</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1212/WNL.41.4.479</pub-id><pub-id pub-id-type="pmid">2011243</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Consortium to Establish a Registry for Alzheimer Disease Neuropathological Assessment. <ext-link ext-link-type="uri" xlink:href="http://cerad.mc.duke.edu/Neuropathology.htm">http://cerad.mc.duke.edu/Neuropathology.htm</ext-link>. Accessed 24/08/2015.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol.</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/BF00308809</pub-id><pub-id pub-id-type="pmid">1759558</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title><source>Acta Neuropathol.</source><year>2006</year><volume>112</volume><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1007/s00401-006-0127-z</pub-id><pub-id pub-id-type="pmid">16906426</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><etal/></person-group><article-title>National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease</article-title><source>Alzheimers Dement.</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmid">22265587</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><etal/></person-group><article-title>National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach</article-title><source>Acta Neuropathol.</source><year>2012</year><volume>123</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmid">22101365</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Staging of Alzheimer's disease-related neurofibrillary changes</article-title><source>Neurobiol Aging.</source><year>1995</year><volume>16</volume><fpage>271</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0197-4580(95)00021-6</pub-id><pub-id pub-id-type="pmid">7566337</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>CR</given-names></name><name><surname>Mukaetova-Ladinska</surname><given-names>EB</given-names></name><name><surname>Hills</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>PC</given-names></name><name><surname>Montejo De Garcini</surname><given-names>E</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease</article-title><source>Proc Natl Acad Sci U S A</source><year>1991</year><volume>88</volume><fpage>5842</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.13.5842</pub-id><pub-id pub-id-type="pmid">1905817</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondareff</surname><given-names>W</given-names></name><name><surname>Wischik</surname><given-names>CM</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><name><surname>Amos</surname><given-names>WB</given-names></name><name><surname>Klug</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Molecular analysis of neurofibrillary degeneration in Alzheimer's disease. An immunohistochemical study</article-title><source>Am J Pathol</source><year>1990</year><volume>137</volume><fpage>711</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">2169192</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria</article-title><source>J Neural Transm.</source><year>1998</year><volume>105</volume><fpage>801</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s007020050096</pub-id><pub-id pub-id-type="pmid">9869320</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondareff</surname><given-names>W</given-names></name><name><surname>Wischik</surname><given-names>CM</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease</article-title><source>Am J Pathol.</source><year>1991</year><volume>139</volume><fpage>641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1909492</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Ksiezak-Reding</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name></person-group><article-title>A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration</article-title><source>Acta Neuropathol.</source><year>1987</year><volume>73</volume><fpage>254</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF00686619</pub-id><pub-id pub-id-type="pmid">2441560</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegami</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Katsuragi</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules</article-title><source>Psychiatry Clin Neurosci.</source><year>1996</year><volume>50</volume><fpage>137</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.1996.tb01678.x</pub-id><pub-id pub-id-type="pmid">9201760</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Hoozemans</surname><given-names>JJ</given-names></name><name><surname>Rozemuller</surname><given-names>AJ</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><etal/></person-group><article-title>Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response</article-title><source>Acta Neuropathol.</source><year>2011</year><volume>122</volume><fpage>577</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0871-6</pub-id><pub-id pub-id-type="pmid">21935637</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzer</surname><given-names>M</given-names></name><name><surname>Gartner</surname><given-names>U</given-names></name><name><surname>Stobe</surname><given-names>A</given-names></name><name><surname>Hartig</surname><given-names>W</given-names></name><name><surname>Gruschka</surname><given-names>H</given-names></name><name><surname>Bruckner</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus</article-title><source>Acta Neuropathol.</source><year>2002</year><volume>104</volume><fpage>471</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12410395</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Quijada</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name></person-group><article-title>Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies</article-title><source>J Neuropathol Exp Neurol.</source><year>1988</year><volume>47</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1097/00005072-198807000-00001</pub-id><pub-id pub-id-type="pmid">2838588</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Simchowicz T. Histologische Studien uber die senile Demenz. Histologische und histopathologische Arbeiten uber die Grosshirnrinde (Histological studies of senile dementia. Histological and histopathological work over the cerebral cortex.). 1911;4:267&#x02013;444.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Iizuka</surname><given-names>T</given-names></name><name><surname>Yanagisawa</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name></person-group><article-title>Reexamination of granulovacuolar degeneration</article-title><source>Acta Neuropathol.</source><year>1991</year><volume>82</volume><fpage>340</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF00296544</pub-id><pub-id pub-id-type="pmid">1722607</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mena</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>PC</given-names></name><name><surname>Harrington</surname><given-names>CR</given-names></name><name><surname>Mukaetova-Ladinska</surname><given-names>EB</given-names></name><name><surname>Wischik</surname><given-names>CM</given-names></name></person-group><article-title>Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease</article-title><source>Acta Neuropathol.</source><year>1996</year><volume>91</volume><fpage>633</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s004010050477</pub-id><pub-id pub-id-type="pmid">8781663</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>MJ</given-names></name><name><surname>Lo</surname><given-names>P</given-names></name></person-group><article-title>Granulovacuolar degeneration in the ageing brain and in dementia</article-title><source>J Neuropathol Exp Neurol.</source><year>1977</year><volume>36</volume><fpage>474</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1097/00005072-197705000-00006</pub-id><pub-id pub-id-type="pmid">870622</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Shibayama</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Ishihara</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Granulovacuolar degeneration in the hippocampal cortex of aging and demented patients&#x02014;a quantitative study</article-title><source>Acta Neuropathol.</source><year>1992</year><volume>85</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/BF00304627</pub-id><pub-id pub-id-type="pmid">1285490</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>BE</given-names></name><name><surname>Kitchener</surname><given-names>D</given-names></name></person-group><article-title>Granulovacuolar degeneration of hippocampal pyramidal cells</article-title><source>J Pathol.</source><year>1972</year><volume>106</volume><fpage>165</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/path.1711060305</pub-id><pub-id pub-id-type="pmid">4114032</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kurashige</surname><given-names>T</given-names></name><name><surname>Dohi</surname><given-names>E</given-names></name><name><surname>Hiji</surname><given-names>M</given-names></name><etal/></person-group><article-title>Granulovacuolar degenerations appear in relation to hippocampal phosphorylated tau accumulation in various neurodegenerative disorders</article-title><source>PLoS ONE.</source><year>2011</year><volume>6</volume><fpage>e26996</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026996</pub-id><pub-id pub-id-type="pmid">22073234</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>C</given-names></name><name><surname>DeMaggio</surname><given-names>AJ</given-names></name><name><surname>Ghoshal</surname><given-names>N</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name><name><surname>Kuret</surname><given-names>J</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases</article-title><source>Neurobiol Aging.</source><year>2000</year><volume>21</volume><fpage>503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00110-X</pub-id><pub-id pub-id-type="pmid">10924763</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>DM</given-names></name></person-group><article-title>Granulovacuolar degeneration in pyramidal cells of the hippocampus</article-title><source>Acta Neuropathol.</source><year>1978</year><volume>42</volume><fpage>149</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/BF00690983</pub-id><pub-id pub-id-type="pmid">654886</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>MJ</given-names></name></person-group><article-title>Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitative study</article-title><source>Acta Neuropathol</source><year>1978</year><volume>42</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/BF00690970</pub-id><pub-id pub-id-type="pmid">654888</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keage</surname><given-names>HA</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Wharton</surname><given-names>SB</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cc75C: Impact of less common and &#x02018;disregarded&#x02019; neurodegenerative pathologies on dementia burden in a population-based cohort</article-title><source>J Alzheimers Dis.</source><year>2012</year><volume>28</volume><fpage>485</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">22045491</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>E</given-names></name><name><surname>O'Connor</surname><given-names>DW</given-names></name><name><surname>Pollitt</surname><given-names>PA</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Cohort profile: the Cambridge City over-75s Cohort (CC75C)</article-title><source>Int J Epidemiol.</source><year>2007</year><volume>36</volume><fpage>40</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ije/dyl293</pub-id><pub-id pub-id-type="pmid">17510074</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>APA</collab></person-group><source>Diagnostic and statistical manual of mental disorders. DSM-III-R</source><year>1987</year><publisher-loc>Washington</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>M</given-names></name><name><surname>Tym</surname><given-names>E</given-names></name><name><surname>Mountjoy</surname><given-names>CQ</given-names></name><name><surname>Huppert</surname><given-names>FA</given-names></name><name><surname>Hendrie</surname><given-names>H</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><etal/></person-group><article-title>CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia</article-title><source>Br J Psychiatry</source><year>1986</year><volume>149</volume><fpage>698</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1192/bjp.149.6.698</pub-id><pub-id pub-id-type="pmid">3790869</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><name><surname>Chou</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science.</source><year>2006</year><volume>314</volume><fpage>130</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1126/science.1134108</pub-id><pub-id pub-id-type="pmid">17023659</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname><given-names>JR</given-names></name><name><surname>Davies</surname><given-names>RR</given-names></name><name><surname>Xuereb</surname><given-names>JH</given-names></name><name><surname>Casey</surname><given-names>B</given-names></name><name><surname>Broe</surname><given-names>M</given-names></name><name><surname>Bak</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Clinicopathological correlates in frontotemporal dementia</article-title><source>Ann Neurol.</source><year>2004</year><volume>56</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1002/ana.20203</pub-id><pub-id pub-id-type="pmid">15349867</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwet</surname><given-names>KL</given-names></name></person-group><article-title>Computing inter-rater reliability and its variance in the presence of high agreement</article-title><source>Br J Math Stat Psychol.</source><year>2008</year><volume>61</volume><fpage>29</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1348/000711006X126600</pub-id><pub-id pub-id-type="pmid">18482474</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>JR</given-names></name><name><surname>Koch</surname><given-names>GG</given-names></name></person-group><article-title>The measurement of observer agreement for categorical data</article-title><source>Biometrics.</source><year>1977</year><volume>33</volume><fpage>159</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.2307/2529310</pub-id><pub-id pub-id-type="pmid">843571</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases</article-title><source>Clin Neuropathol.</source><year>2010</year><volume>29</volume><fpage>271</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.5414/NPP29271</pub-id><pub-id pub-id-type="pmid">20860890</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussiere</surname><given-names>T</given-names></name><name><surname>Gold</surname><given-names>G</given-names></name><name><surname>Kovari</surname><given-names>E</given-names></name><name><surname>Giannakopoulos</surname><given-names>P</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name><name><surname>Perl</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease</article-title><source>Neuroscience.</source><year>2003</year><volume>117</volume><fpage>577</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00942-9</pub-id><pub-id pub-id-type="pmid">12617964</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>DL</given-names></name><name><surname>Altschuler</surname><given-names>RJ</given-names></name><name><surname>Struble</surname><given-names>RG</given-names></name><name><surname>Casanova</surname><given-names>MF</given-names></name><name><surname>Cork</surname><given-names>LC</given-names></name><name><surname>Murphy</surname><given-names>DB</given-names></name></person-group><article-title>Sequestration of tubulin in neurons in Alzheimer's disease</article-title><source>Brain Res.</source><year>1986</year><volume>385</volume><fpage>305</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(86)91077-2</pub-id><pub-id pub-id-type="pmid">3096492</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellani</surname><given-names>RJ</given-names></name><name><surname>Gupta</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>B</given-names></name><name><surname>Siedlak</surname><given-names>SL</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Coller</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules</article-title><source>Lab Invest.</source><year>2011</year><volume>91</volume><fpage>1777</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2011.149</pub-id><pub-id pub-id-type="pmid">21968813</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>MJ</given-names></name></person-group><article-title>Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study</article-title><source>Acta Neuropathol</source><year>1977</year><volume>37</volume><fpage>111</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF00692056</pub-id><pub-id pub-id-type="pmid">848276</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadokura</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Kakuda</surname><given-names>S</given-names></name><name><surname>Makioka</surname><given-names>K</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration</article-title><source>Neurosci Lett.</source><year>2009</year><volume>463</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.06.024</pub-id><pub-id pub-id-type="pmid">19539703</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>C</given-names></name><name><surname>Dinekov</surname><given-names>M</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group><article-title>Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Abeta amyloidosis</article-title><source>Neurobiol Dis.</source><year>2014</year><volume>71</volume><fpage>169</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.07.006</pub-id><pub-id pub-id-type="pmid">25073087</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>H</given-names></name><name><surname>Gustafsson</surname><given-names>E</given-names></name><name><surname>Svensson</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Sunnemark</surname><given-names>D</given-names></name><etal/></person-group><article-title>MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies</article-title><source>Acta Neuropathol Commun.</source><year>2014</year><volume>2</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-2-22</pub-id><pub-id pub-id-type="pmid">24533944</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmel</surname><given-names>G</given-names></name><name><surname>Mager</surname><given-names>EM</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name><name><surname>Kuret</surname><given-names>J</given-names></name></person-group><article-title>The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology</article-title><source>J Biol Chem.</source><year>1996</year><volume>271</volume><fpage>32789</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.51.32789</pub-id><pub-id pub-id-type="pmid">8955115</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Nakazato</surname><given-names>Y</given-names></name><name><surname>Kawarabayashi</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name><name><surname>Morimatsu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Extracellular neurofibrillary tangles associated with degenerating neurites and neuropil threads in Alzheimer-type dementia</article-title><source>Acta Neuropathol.</source><year>1991</year><volume>81</volume><fpage>603</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/BF00296369</pub-id><pub-id pub-id-type="pmid">1882636</pub-id></element-citation></ref></ref-list></back></article>